Savara宣布英国药品和保健品管理局接受Molgradex上市许可申请用于治疗自身免疫性肺泡蛋白沉积症

美股速递
Apr 07

Savara Inc. 宣布,英国药品和保健品管理局(MHRA)已正式受理其药物Molgradex®用于治疗自身免疫性肺泡蛋白沉积症(autoimmune PAP)的上市许可申请(MAA)。这一进展标志着该药物在英国监管审批流程中迈出了关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10